Three Biotechs That Takeover: Top 2026 M&A Targets
As large pharma hunts for GLP-1 and cardiovascular assets, three biotechs stand out as hot takeover targets. This rep...
GLP-1
This tag page compiles 4 articles on GLP-1 trends, pricing, and weight-loss stock impacts, helping you understand how drug costs and market moves affect personal finances.
13 articles
Should Lilly Investors Worry About Its Rival From Within
Eli Lilly dominates the GLP-1 space, but competition is heating up from outside and inside its own lineup. This guide...
Is Novo Nordisk's Rebound Real--Or Head Fake for Investors?
After a steep slide, Novo Nordisk has shown fresh momentum. But can the rebound sustain, or is it just a temporary bo...
Will Medicare Cover Ozempic? What Retirees Should Know About GLP-1 Coverage
GLP-1 drugs like Ozempic and Wegovy are changing the cost landscape for retirees. This guide breaks down what Medicar...
Forget Oral Wegovy: This Could Be a Bigger Win for Investors
The launch of oral Wegovy marked a turning point for weight-loss drugs and stock investors. But a newer, rival oral G...
Lilly Falls on Oral Obesity Pill as FDA Decision Looms
Eli Lilly stock fell about 5% as investors awaited the FDA's April decision on orforglipron. Novo Nordisk's intensifi...
Is There Much Bullishness Priced Into Eli Lilly Stock?
Eli Lilly has enjoyed rapid growth from GLP-1 drugs, but sky-high expectations invite questions about valuations. Thi...
Lilly Just Opened Door to a GLP-1 Growth Boom in Markets
Eli Lilly unveiled a direct-to-employer program for Zepbound, aiming to accelerate GLP-1 adoption and expand market s...
Health Startup Noom Adding GLP-1 Drugs to Med Plan Now
Noom is shifting from psychology-based weight loss to prescription treatments, launching Noom Med in a multi-state ro...
Novo Nordisk Slashing Prices Could Boost the Stock
Novo Nordisk slashing prices is drawing attention from investors who wonder how a price cut could actually lift the s...
Better Weight Loss Stock: Novo Nordisk vs Amgen Showdown
The weight loss field is heating up, with Novo Nordisk leading the GLP-1 wave and Amgen pursuing a smaller, more sele...
Forget Ozempic: This High-Flying Device Maker Stands Strong
In a world obsessed with weight-loss drugs, a different growth engine quietly powers ahead. This article explains why...